Subject demographic characteristics at baseline
| Mavrilimumab (mg/kg) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Parameter | Placebo (n = 5) | All mavrilimumab (n = 27) | 0.01 (n = 1) | 0.03 (n = 1) | 0.1 (n = 5) | 0.3 (n = 5) | 1.0 (n = 5) | 3.0 (n = 5) | 10.0 (n = 5) |
| No. of subjects who completed the study | 5 | 27 | 1 | 1 | 5 | 5 | 5 | 5 | 5 |
| Age (years) | 53 ± 6.8 | 53 ± 10.4 | 67 | 33 | 47 ± 5.8 | 55 ± 4.3 | 46 ± 13.8 | 57 ± 6.1 | 58 ± 10.5 |
| Gender, n | |||||||||
| Male | 0 | 4 | 0 | 1 | 0 | 1 | 0 | 1 | 1 |
| Female | 5 | 23 | 1 | 0 | 5 | 4 | 5 | 4 | 4 |
| White race, n (%) | 5 (100) | 27 (100) | 1 (100) | 1 (100) | 5 (100) | 5 (100) | 5 (100) | 5 (100) | 5 (100) |
| Methotrexate (mg/day) | 14.0 ± 2.2 | 16 ± 3.2 | 20.0 | 15.0 | 16.0 ± 5.7 | 16.0 ± 2.2 | 16.0 ± 2.2 | 15.0 ± 3.5 | 16.0 ± 2.2 |
| DAS28 | 3.79 ± 1.0 | 3.35 ± 0.9 | 4.35 | 3.46 | 3.08 ± 0.5 | 3.91 ± 0.4 | 3.58 ± 0.8 | 3.29 ± 1.4 | 2.69 ± 0.9 |
| Tender joints | 4 ± 3.6 | 3 ± 2.9 | 3 | 4 | 1 ± 1.0 | 4 ± 2.7 | 3 ± 3.3 | 3 ± 2.3 | 3 ± 4.7 |
| Swollen joints | 2 ± 1.5 | 1 ± 1.2 | 0 | 1 | 0 ± 0.0 | 1 ± 0.5 | 2 ± 2.5 | 1 ± 0.9 | 0 ± 0.5 |
| CRP (mg/l) | 5.7 ± 6.0 | 6.6 ± 9.4 | 47.8 | 4.1 | 4.7 ± 3.7 | 5.1 ± 3.3 | 6.4 ± 6.1 | 7.3 ± 7.4 | 1.7 ± 0.5 |
| ESR (mm/h) | 17.0 ± 7.5 | 18.0 ± 12.4 | 50.0 | 10.0 | 25.0 ± 13.2 | 18.0 ± 11.6 | 16.0 ± 3.6 | 19.0 ± 12.7 | 6.0 ± 1.6 |
| Weight (kg) | 73.9 ± 15.9 | 76.7 ± 16.7 | 85.6 | 86.1 | 66.1 ± 21.3 | 71.6 ± 14.4 | 82.0 ± 16.9 | 79.1 ± 18.8 | 80.7 ± 15.3 |
| HAQ (score 0–3) | 1.60 ± 0.41 | 1.61 ± 0.33 | 1.50 | 1.250 | 1.700 ± 0.29 | 1.775 ± 0.45 | 1.600 ± 0.14 | 1.525 ± 0.37 | 1.550 ± 0.44 |
Medical history terms were classified according to the terminology of the Medical Dictionary for Regulatory Activities (version 11). Values are mean ± SD unless otherwise noted.
CRP, C-reactive protein; DAS28, Disease Activity Score 28-joint assessment; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire.